A study published in the Circulation journal evaluated the impact of 2-year treatment with rosuvastatin on carotid intima media thickness in children with heterozygous familial hypercholesterolemia (HeFH). The study cohort involved children with HeFH (age: 6 – < 18 years) and low-density lipoprotein cholesterol > 4.9 mmol/L or > 4.1 mmol/L in combination with other risk factors. They were administered rosuvastatin for 2 years, starting at 5 mg once daily, with up-titration to 10 mg (age: 6 – < 10 years) or 20 mg (age: 10 – < 18 years). The findings revealed that rosuvastatin therapy led to significantly less progression of increased carotid intima media thickness in children with HeFH than in untreated unaffected siblings. The researchers also emphasized the importance of early commencement of statin treatment for low-density lipoprotein cholesterol reduction in children with HeFH.